EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSAMXG00000007103
Gene Symbol: MAP3K5
3 Cross references
205 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSAMXG00000043547
Gene Symbol: MAP3K8
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSAMXG00000021475
Gene Symbol: MAP3K9
1 Cross references
196 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSAMXG00000039283
Gene Symbol: MGLL
3 Cross references
209 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5

Ensembl ID : ENSAMXG00000024864
Gene Symbol: LOC103025843
3 Cross references
195 Possible Orthologues:

Natriuretic Peptide Receptor 1a

Ensembl ID : ENSAMXG00000011429
Gene Symbol: NPR1A
1 Cross references
196 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSAMXG00000018355
Gene Symbol: NPR2
3 Cross references
191 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSAMXG00000019445
Gene Symbol: NPR3
3 Cross references
210 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1

Ensembl ID : ENSAMXG00000014597
Gene Symbol: LOC103034623
3 Cross references
195 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSAMXG00000014174
Gene Symbol: LOC103025197
3 Cross references
200 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2

Ensembl ID : ENSAMXG00000017646
Gene Symbol: LOC103042072
3 Cross references
194 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSAMXG00000007180
Gene Symbol: LOC103047822
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).